Editorials

Effects of Low-dose Infliximab on Spinal Inflammation on Magnetic Resonance Imaging in Ankylosing Spondylitis
M. Rudwaleit ........................................ 1553

Beyond Early Diagnosis: Occult Psoriatic Arthritis
C. Palazzi, E. Lubrano, S. D’Angelo, I. Olivieri ............ 1556

Are There Patients with Inflammatory Disease Who Do Not Respond to Prednisone? D. Sen, R. Rajbhandary, A. Cartlino, R.J. Anderson, P.H. Schur, R.S. Panush .......... 1559

Reviews

Educational Interventions for Implementation of Arthritis Clinical Practice Guidelines in Primary Care: Effects on Health Professional Behavior S.C. Lineker, J.A. Husted 1562

Improving the Routine Management of RA: The Value of Tight Control P.J. Mease ......................... 1570

Articles

Influence of IL6R rs8192284 Polymorphism Status in Disease Activity in RA J.R. Lamas, L. Rodríguez-Rodríguez, J. Varadé, et al .................... 1579


Soluble LILRA3, a Potential Natural Antiinflammatory Protein, Is Increased in Patients with RA and Is Tightly Regulated by IL-10, TNF-α, and IFN-γ H. An, V. Chandra, B. Piraino, et al ........................ 1596

A Modified RA Disease Activity Score Without Acute-phase Reactants (mDAS28) for Epidemiological Research M.J. Bentley, J.D. Greenberg, G.W. Reed .................. 1607

Scale Characteristics and Mapping Accuracy of the US EQ-5D, UK EQ-5D, and SF-6D in Patients with RA F. Wolfe, K. Michaud, G. Wallenstein ...................... 1615


Increased Expression of Phospholipid Scramblase 1 in Monocytes from Patients with SLE E. Suzuki, O. Amengual, T. Atsumi, et al ............. 1639

Raloxifene Modulates Estrogen-mediated B Cell Autoreactivity in NZB/W F1 Mice Y. Zhang, S. Saha, G. Rosenfeld, J. Gonzalez, K.P. Fepeljugoski, E. Peeva .... 1646

Altered Expression of TNF-α Signaling Pathway Proteins in SLE L.-J. Zhu, C. Landolt-Marticorena, T. Li, et al ............ 1658

Serum Albumin as a Marker for Disease Activity in Patients with SLE J. Yip, E. Aghdassi, J. Su, et al .......................... 1667

Functional Variants of Fc Gamma Receptor (FCGR2A) and FCGR3A Are Not Associated with Susceptibility to SSc in a Large European Study (EUSTAR) B.Z. Alizadeh, J. Broen, B. Rueda, et al, and EUSTAR ....................... 1673


Ultrasound Elastography Assessment of Skin Involvement in SS: Lights and Shadows A. Iagnocco, O. Kaloudi, C. Perella, et al ............ 1688

The Symptom Burden Index: Development and Initial Findings from Use with Patients with SSc M.A. Kallen, M.D. Mayes, Y.L. Kriseman, S.B. de Achaval, V.L. Cox, M.E. Suarez-Almazor ......................... 1692

Tumor Necrosis Factor-α Blockers in SAPHO Syndrome K. Ben Abdelghani, D.G. Dran, J.-E. Gottenberg, J. Morel, J. Sibilia, B. Combe ............................ 1699

Renal Transplant in Wegener’s Granulomatosis Compared to Microscopic Polyangiitis D. Geetha, M. Haas, E.S. Kraus, H. Rabb, P. Seo .................. 1705

Enthesitis and Related Changes in the Knees in Seronegative SpA and Skin Psoriasis: MRI Case-Control Study Y. Emad, Y. Ragab, I. Bassouyouni, et al .................. 1709

Prognostic Significance of MRI Changes of the Sacroiliac Joints in SpA — A Followup Study K.B. Madsen, B. Schiøttz-Christensen, A.G. Jurik ........................ 1718

Low-dose Infliximab (3 mg/kg) Significantly Reduces Spinal Inflammation on MRI in Patients with AS: A Randomized Placebo-controlled Study W.P. Maksymowych, D. Salonen, R.D. Inman, P. Rahman, R.G.W. Lambert, for the CANDLE Study Group .................. 1728

Reactive Arthritis and Other Musculoskeletal Sequelae Following an Outbreak of Salmonella hadar in Castellon, Spain A. Arnedo-Peña, J. Beltrán-Fabregat, B. Vila-Pastor, et al .................. 1735
Diagnosis of Chronic Gout: Evaluating the ACR Proposal, EULAR Recommendations, and Clinical Judgment
I. Peláez-Ballestas, C. Hernández Cuevas, R. Burgos-Vargas, et al ........................................ 1743

Strategies to Improve Recruitment into Rheumatology: Results of the Workforce in Rheumatology Issues Study (WRIST)
S. Zborovski, G. Rohekar, S. Rohekar ........................................ 1749

Pediatric Rheumatology
Profile of Indian Patients with Juvenile Onset Chronic Inflammatory Joint Disease Using the ILAR Classification Criteria for JIA: A Community-based Cohort Study
V. Kunjir, A. Venugopalan, A. Chopra ........................................ 1756

Effectiveness of Leflunomide in Patients with JIA in Clinical Practice
I. Foeldvari, A. Wierk ........................................ 1763

Cerebral and Cerebellar Volume Loss in Children and Adolescents with SLE: A Review of Clinically Acquired Brain MRI
E. Muscal, E. Traipe, M.M. de Guzman, B.L. Myones, R.L. Brey, J.V. Hunter ........................................ 1768

Images in Rheumatology
Lupus Related Longitudinal Myelitis
P. Zotos, J. Poularas, D. Karakitsos, A. Karabinis. 1776

Letters
Development of Anti-CCP-positive RA Following Pegylated IFN-α2a Treatment for Chronic Hepatitis C Infection
T.-L. Fong, D. Yang, D. Arkfeld ........................................ 1777

Multifocal Motor Neuropathy with Conduction Block Following Treatment with Infliximab
C.E. Barber, P. Lee, A.H. Steinhart, J. Lazarou. 1778

Successful Treatment with Infliximab of a Patient with TNF-associated Periodic Syndrome (TRAPS) Who Failed to Respond to Etanercept
M. Krelenbaum, A. Chaiton ........................................ 1780

Rituximab Treatment in a Child with Rosai-Dorfman Disease and SLE

Reactivated Varicella Zoster Virus May Cause Peripheral Arterial Thrombosis
T.K. Teksut, A.B. Önal, M.A. Öztürk, M.E. Tezcan ........................................ 1785

Coexistent Wegener's Granulomatosis and Goodpasture's Disease
S. Mulpuru, C. Touchie, J. Karpinski, S. Humphrey-Murto ........................................ 1786

Book Review
Ankylosing Spondylitis. 1788

Correction
Oral Contraceptives and Systemic Lupus Erythematosus, Current Practice in Hamilton [abstract]
S. Dixit, S. Waserman, N. Khalidi ........................................ 1788

Meetings in Rheumatology ........................................ xiv